… Other molecular aspects of pharmacology, which add an additional layer of complexity to …
to be resolved after discontinuation of the drug. Paradoxically, anti-TNF-α agents have been …

… of biosimilars of the anti-TNF agents allow drug costs to be … used in all patients initiating an
anti-TNF agent as a means to … dosing based on clinical features (the maintenance phase). In …

… In this review, we briefly introduce the drug utilization, effectiveness, … One aspect should be
taken into consideration is that … of action of anti-TNF therapy in inflammatory bowel disease. J. …

… biosimilar drug, extensive comparability exercises, including physicochemical characteristics
… ): A total of 459 patients were naïve to anti-TNF-α therapy, 196 had a previous exposure to …

… with IBD has increased, biosimilars have become available, … drug, commercialized as
Remicade ® , was the first anti-TNF … characteristics are known to predict response to anti-TNF …

… Abstract: Background: Anti-tumor necrosis factor (anti-TNF) … Characteristics of the main
randomized controlled trials … 21 (5.3%) patients had infusion reactions leading to drug withdrawal …

… the approval of biosimilars differs from that of original drug products [14… Patients who had
previously received anti-TNF therapy … comparable rates and characteristics of infusion reactions …

… influence the pharmacology of the biosimilar and their … , the biosimilar must demonstrate
several features, including … Our current FDA-approved, anti-TNF biosimilars are not deemed …

… the role of biosimilars in inflammatory bowel disease in terms … in patients has the potential
for large drug-acquisition cost-… and biological characteristics of the infliximab biosimilar SB2, …

… inflammatory diseases (IMIDs) are chronic conditions that share common pathophysiological
pathways and include rheumatoid arthritis (RA), inflammatory bowel disease (… global drug …